This is Morria’s first human study in allergic rhinitis (AR). The anti-inflammatory drug, MRX-4 is nasally administered as a single dose either with or without an allergen challenge to determine tolerance. Results are expected by the end of the fourth quarter of 2007.
Yuval Cohen, president of Morria, said: “We are excited to be taking this significant step toward introducing a potentially safer, more effective and more affordable treatment option to the multibillion-dollar AR market.”
Peter Barnes, a professor at the National Heart & Lung Institute at Imperial College in London and Morria scientific advisory board member, said: “There is a real and urgent need for novel, non-steroidal treatments for inflammatory diseases such as allergic rhinitis. Morria’s drug platform could potentially offer such an alternative.”